Beilu Pharmaceutical (300016.SZ) has been awarded the registration certificate for Iomeprol Injection.

Zhitong Finance APP News, Beilu Pharmaceutical (300016.SZ) announced that the company has recently received the "Drug Registration Certificate" for Iopamidol Injection approved and issued by the National Medical Products Administration. Iopamidol Injection is developed by Bracco in Italy, and is a non-ionic monomeric X-ray contrast agent. The product has excellent physical and chemical properties and, compared with other types of non-ionic monomeric X-ray contrast agents at the same concentration, has the lowest osmotic pressure and lower viscosity. It is also stable in terms of its physical and chemical properties and does not require the addition of chelating agents. Indications include: intravenous urography (adults, including those with kidney damage or diabetes), CT (trunk), conventional angiography, arterial DSA, cardiovascular angiography (adults and children), routine selective coronary angiography, interventional coronary angiography, fistulography, ductography, lacrimal duct imaging, and salivary duct imaging.